November 28, 2024 - 08:51

In a significant move, former President Donald Trump has selected a Stanford University professor known for his critical stance on COVID-19 lockdowns to lead a key health agency. This appointment comes as part of Trump’s ongoing efforts to reshape health policy and address public health challenges in the wake of the pandemic. The professor, who has gained attention for advocating against strict lockdown measures, is expected to bring a controversial perspective to the role.
Before officially assuming the position, the appointee will need to secure confirmation from the U.S. Senate, a process that could spark intense debate given the professor's previous comments and the current political climate surrounding public health policies. Trump's choice reflects his commitment to appointing individuals who align with his views on government intervention and public health measures. As the nation continues to navigate the complexities of health care and pandemic response, this appointment is poised to influence future strategies and discussions within the health sector.
July 23, 2026 - 15:06
Good riddance to bundled ‘global’ maternal care billingThe American College of Obstetricians and Gynecologists is welcoming a major shift in how pregnancy and childbirth are billed. For years, the system relied on a single, bundled `global` fee that...
July 22, 2026 - 21:50
West Nile virus found in two mosquito traps in DeKalb County, health officials sayHealth authorities in DeKalb County have confirmed that mosquitoes collected from two separate traps have tested positive for the West Nile virus. The positive samples were identified during...
July 22, 2026 - 08:37
Bradford A&E services downgraded by health watchdogA health watchdog has downgraded the accident and emergency services at Bradford Royal Infirmary following an inspection that uncovered significant concerns. The Care Quality Commission (CQC) found...
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...